LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

LLY

914.82

+1.5%↑

JNJ

239.95

+2.09%↑

ABBV

206.56

+0.92%↑

NVS

150.73

+1.58%↑

MRK

119.31

+2.59%↑

Home・Aandelen Lijst・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

459.01 3.23

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

444.87

Max

470.87

Belangrijke statistieken
By Trading Economics
Inkomsten	56M -59M
Verkoop	34M 321M
Winstmarge	-18.243
Werknemers	915
EBITDA	56M -50M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+58.39% upside

Dividenden
By Dow Jones
Volgende Winsten	30 apr 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-284M 10B
Vorige openingsprijs	455.78
Vorige sluitingsprijs	459.01

Nieuwssentiment

By Acuity

11%

89%

6 / 350 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

263.2 / 277.1 Steun & Weerstand

Madrigal Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 mrt 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Infosys Agrees to Acquire Stratus

25 mrt 2026, 23:58 UTC

Winsten

Guming Proposes 2025 Final Dividend of HK$0.50 >1364.HK

25 mrt 2026, 23:58 UTC

Winsten

Guming: Seek to Further Expand Coffee Product Line, Explore New Food Categories >1364.HK

25 mrt 2026, 23:57 UTC

Winsten

Guming: Aim to Expand Store Network in China, Evaluate Overseas Opportunities >1364.HK

25 mrt 2026, 23:57 UTC

Winsten

Guming Store Network Rose 37% on Year to 13,554 Stores as of Dec. 31, 2025 >1364.HK

25 mrt 2026, 23:56 UTC

Winsten

Guming 2025 Rev CNY12.91B Vs. CNY8.79B >1364.HK

25 mrt 2026, 23:56 UTC

Winsten

Guming 2025 Net CNY3.11B Vs. Net CNY1.48B >1364.HK

25 mrt 2026, 23:41 UTC

Marktinformatie

Nikkei May Trade Rangebound Amid Uncertainty Over U.S.-Iran Talks -- Market Talk

25 mrt 2026, 23:41 UTC

Winsten

These Stocks Are Today's Movers: Arm, Intel, AMD, Firefly Aerospace, Robinhood, JD.com, Sarepta, and More -- Barrons.com

25 mrt 2026, 23:34 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Declines on Possible Technical Correction -- Market Talk

25 mrt 2026, 22:08 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

25 mrt 2026, 22:08 UTC

Marktinformatie

Synlait Milk's Outlook Depends on Dunsandel -- Market Talk

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy: Weak Consumer Demand Weighed on Rev >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy Plans Steady Increase in Dividends For Next Three Years >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy: 2025 Net Supported by Absence of Impairment Provisions Made Last Year >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy 2025 Rev CNY82.24B Vs. CNY88.67B >2319.HK

25 mrt 2026, 22:07 UTC

Winsten

China Mengniu Dairy 2025 Net CNY1.55B Vs. Net CNY104.51M >2319.HK

25 mrt 2026, 21:58 UTC

Marktinformatie

Amplitude Energy Oversold on Isabella-1 Well Disappointment -- Market Talk

25 mrt 2026, 21:37 UTC

Marktinformatie

Miran: AI and Deregulation Are Positive Supply Shocks To Economy -- Market Talk

25 mrt 2026, 21:14 UTC

Acquisities, Fusies, Overnames

St Barbara: Expects to Record Gain on Sale of Roughly A$500 Million Upon Completion

25 mrt 2026, 21:13 UTC

Acquisities, Fusies, Overnames

St Barbara: All Conditions Satisfied, Waived on Lingbao Deal

25 mrt 2026, 21:12 UTC

Acquisities, Fusies, Overnames

Closing M&A Deals Bring Opportunity. Janus Henderson and Other Stocks to Buy. -- Barrons.com

25 mrt 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

25 mrt 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

25 mrt 2026, 20:33 UTC

Acquisities, Fusies, Overnames

KKR & Co.: Entered Agreement to Sell CoolIT Systems to Ecolab in Transaction Valued at $4.75B >KKR >KKR

25 mrt 2026, 20:31 UTC

Winsten

The SpaceX IPO Is Coming. Cathie Wood's Ark Venture and More Funds to Get in on the Action. -- Barrons.com

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

KKR Scores One of Its Best Bets With Sale of Data-Center Cooling Business -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

CoolIT Employees Set to Receive Average Payouts of $240,000, Executives Say -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

CoolIT Deal Ranks Among KKR's Top-4 Highest Earning Investments in Past 20 Years, Executives Say -- WSJ

25 mrt 2026, 20:15 UTC

Acquisities, Fusies, Overnames

KKR Set to Make 15x Investment From $4.75B Sale of CoolIT to Ecolab, Executives Say -- WSJ

Peer Vergelijking

Prijswijziging

Madrigal Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

58.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 704.88 USD 58.39%

Hoogste 964 USD

Laagste 529 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Madrigal Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Madrigal Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

263.2 / 277.1Steun & Weerstand

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

6 / 350 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.